Up-regulation of microglial cathepsin C expression and activity in lipopolysaccharide-induced neuroinflammation

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Fan, Kai ^a   Wu, Xuefei ^a   Fan, Bin ^a   Li, Ning ^b   Lin, Yongzhong ^a   Yao, Yiwen ^a   Ma, Jianmei ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b General Surgery   (China)

Author keywords

Cathepsin C; Lipopolysaccharide; Microglia; Neuroinflammation

Indexed keywords

DIPEPTIDYL PEPTIDASE I; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL ACTIVATION; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; UPREGULATION;

EID: 84861179515     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-96     Document Type: Article

References (72)

1. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934. 10.1016/j.cell.2010.02.016, 2873093, 20303880.
2. Whitton PS. Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson's disease. Curr Opin Investig Drugs 2010, 11:788-794.
3. Hensley K. Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J Alzheimers Dis 2010, 21:1-14.
4. Herrera AJ, Castano A, Venero JL, Cano J, Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 2000, 7:429-447. 10.1006/nbdi.2000.0289, 10964613.
5. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 2002, 81:1285-1297. 10.1046/j.1471-4159.2002.00928.x, 12068076.
6. Wilms H, Zecca L, Rosenstiel P, Sievers J, Deuschl G, Lucius R. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr Pharm Des 2007, 13:1925-1928.
7. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 1994, 180:147-150. 10.1016/0304-3940(94)90508-8, 7700568.
8. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995, 202:17-20. 10.1016/0304-3940(95)12192-7, 8787820.
9. Muller T, Blum-Degen D, Przuntek H, Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand 1998, 98:142-144.
10. Knott C, Stern G, Wilkin GP. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 2000, 16:724-739. 10.1006/mcne.2000.0914, 11124893.
11. Nagatsu T, Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des 2005, 11:999-1016. 10.2174/1381612053381620, 15777250.
12. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 2007, 150:963-976. 2013918, 17339843.
13. Eikelenboom P, Zhan SS, Van Gool WA, Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci 1994, 15:447-450. 10.1016/0165-6147(94)90057-4, 7886816.
14. Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, Oh KW, Hong JT. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflamm 2008, 5:37.
15. Petanceska S, Canoll P, Devi AL. Expression of rat cathepsin S in phagocytic cells. J Biol Chem 1996, 271:4403-4409. 10.1074/jbc.271.8.4403, 8626791.
16. Ryan RE, Sloane BF, Sameni M, Wood PL. Microglial cathepsin B: an immunological examination of cellular and secreted species. J Neurochem 1995, 65:1035-1045.
17. Kingham PJ, Pocock JM. Microglial apoptosis induced by chromogranin A is mediated by mitochondrial depolarization and the permeability transition but not by cytochrome c release. J Neurochem 2001, 74:1452-1462.
18. Nakanishi H, Tominaga K, Amano T, Hirotsu I, Inoue T, Yamamoto K. Age-related changes in activities and localizations of cathepsins D, E, B, and L in the rat brain tissues. Exp Neurol 1994, 125:1-10. 10.1006/exnr.1994.1001, 7508401.
19. Bernstein HG, Brusziz S, Schmidt D, Wiederanders B, Dorn A. Immunodetection of cathepsin D in neuritic plaques found in brains of patients with dementia of Alzheimer type. J Hirnforsch 1989, 30:613-618.
20. Yoshiyama Y, Arai K, Oli T, Hattori T. Expression of invariant chain and pro-cathepsin L in Alzheimer's brain. Neurosci Lett 2000, 290:125-128. 10.1016/S0304-3940(00)01326-4, 10936693.
21. Czapski GA, Gajkowska B, Strosznajder JB. Systemic administration of lipopolysaccharide induces molecular and morphological alterations in the hippocampus. Brain Res 2010, 1356:85-94.
22. Rawlings ND, Morton FR, Barrett AJ. MEROPS: the peptidase database. Nucleic Acids Res 2006, 34:270-272.
23. Deussing J, Kouadio M, Rehman S, Werber I, Schwinde A, Peters C. Identification and characterization of a dense cluster of placenta-specific cysteine peptidase genes and related genes on mouse chromosome 13. Genomics 2002, 79:225-240. 10.1006/geno.2002.6696, 11829493.
24. Turk B, Turk D, Turk V. Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 2000, 1477:98-111. 10.1016/S0167-4838(99)00263-0, 10708852.
25. Felbor U, Kessler B, Mothes W, Goebel HH, Ploeggh HL, Bronson RT, Olsen BR. Neuronal loss and brain atrophy in mice lacking cathepsin B and L. Proc Natl Acad Sci USA 2002, 99:7883-7888. 10.1073/pnas.112632299, 122989, 12048238.
26. Nakanishi H. Neuronal and microglial cathepsins in aging and age-related diseases. Ageing Res Rev 2003, 2:367-381. 10.1016/S1568-1637(03)00027-8, 14522241.
27. Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene 2008, 27:6434-6451. 10.1038/onc.2008.310, 18955971.
28. Fei XF, Qin ZH, Xiang B, Li LY, Han F, Fukunaga K, Liang ZQ. Olomoucine inhibits cathepsin L nuclear translocation, activates autophagy and attenuates toxicity of 6-hydroxydopamine. Brain Res 2009, 1264:85-97.
29. Ma J, Tanaka KF, Yamada G, Ikenaka K. Induced expression of cathepsins and cystatin C in a murine model of demyelination. Neurochem Res 2007, 32:311-320. 10.1007/s11064-006-9183-y, 17086443.
30. Paris A, Strukelj B, Pungercar J, Renko M, Dolenc I, Turk V. Molecular cloning and sequence analysis of human preprocathepsin C. FEBS Lett 1995, 369:326-330. 10.1016/0014-5793(95)00777-7, 7649281.
31. Turk D, Janjic V, Stern I, Podobnik M, Lamba D, Dahl SW, Lauritzen C, Pedersen J, Turk V, Turk B. Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases. EMBO J 2001, 20:6570-6582. 10.1093/emboj/20.23.6570, 125750, 11726493.
32. Rao NV, Rao GV, Hoidal JR. Human dipeptidyl-peptidase I gene characterization, localization, and expression. J Biol Chem 1997, 11:10260-10265.
33. McGuire MJ, Lipsky PE, Thiele DL. Cloning and characterization of the cDNA encoding mouse dipeptidyl peptidase I (cathepsin C). BBA 1997, 1351:267-273. 10.1016/S0167-4781(97)00021-3, 9130590.
34. Ishidoh K, Muno D, Sato N, Kominami E. Molecular cloning of cDNA for rat cathepsin C. J Biol Chem 1991, 266:16312-16317.
35. McGuire MJ, Lipsky PE, Thiele DL. Purification and characterization of dipeptidyl peptidase I from human spleen. Arch Biochem Biophys 1992, 295:280-288. 10.1016/0003-9861(92)90519-3, 1586157.
36. Pham CTN, Ley TJ. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci USA 1999, 96:8627-8632. 10.1073/pnas.96.15.8627, 17567, 10411926.
37. Sheth PD, Pedersen J, Walls AF, McEuen AR. Inhibition of dipeptidyl peptidase I in the human mast cell line HMC-1: blocked activation of tryptase, but not of the predominant chymotryptic activity. Biochem Pharmacol 2003, 66:2251-2262. 10.1016/j.bcp.2003.08.002, 14609749.
38. Adkison AM, Raptis SZ, Kelley DG, Pham CTN. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest 2002, 109:363-371. 150852, 11827996.
39. Hu Y, Pham CT. Dipeptidyl peptidase I regulates the development of collagen-induced arthritis. Athritis Rheum 2005, 52:2553-2558.
40. Clair MJ, Pham CTN, Villalta A, Caughey GH, Wolters PJ. Mast cell dipeptidyl peptidase I mediates survival from sepsis. J Clin Invest 2004, 113:628-634. 338261, 14966572.
41. Bourbeau J, Johnson M. New and controversial therapies for chronic obstructive pulmonary disease. PATS 2009, 6:553-554.
42. Shi GP. Role of cathepsin C in elastase-induced mouse abdominal aortic aneurysms. Future Cardiol 2007, 3:591-593. 10.2217/14796678.3.6.591, 19804279.
43. Akk AM, Simmons PM, Chan HW, Agapov E, Holtzman MJ, Grayson MH, Pham CTN. Dipeptidyl peptidase I-dependent neutrophil recruitment modulates the inflammatory response to Sendai virus infection. J Immunol 2008, 180:3535-3542. 2597084, 18292580.
44. Qin LY, Wu XF, Block ML, Liu YX, Breese GR, Hong JS, Knapp DJ, Crews FT. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462. 10.1002/glia.20467, 2871685, 17203472.
45. Ma J, Matsumoto M, Tanaka K, Takebayashi H, Ikenaka K. An animal model for late onset chronic demyelinaion disease caused by failed terminal differentiation of oligodendrocyte. Neuron Glia Biol 2006, 2:81-91.
46. Ma J, Tanaka K, Shimizu T. Bernard Claude CA, Kakita A, Takahashi H, Pfeiffer SE, Ikenaka K: Microglial cystatin F expression is a sensitive indicator for ongoing demyelination with concurrent remyelination. J Neurosci Res 2011, 89:639-649. 10.1002/jnr.22567, 21344476.
47. Jones E, Adcock IM, Ahmed BY, Punchard NA. Modulation of LPS stimulated NF-κB mediated nitric oxide production by PKCε and JAK2 in RAW macrophages. J Inflamm 2007, 4:23.
48. Ward RJ, Wilmet S, Legssyer R, Deroy D, Toussaint L, Crichton RR, Pierreux C, Hue L, Piette J, Srai SK, Solanky N, Klein D, Summer K. Iron supplementation to pregnant rats: effects on pregnancy outcome, iron homeostasis and immune function. Biometals 2009, 22:211-223. 10.1007/s10534-008-9155-6, 18690415.
49. Perry VH. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 2004, 18:407-413. 10.1016/j.bbi.2004.01.004, 15265532.
50. Sparkman NL, Martin LA, Calvert WS, Boehm GW. Effects of intraperitoneal lipopolysaccharide on Morris maze performance in year-old and 2-month-old female C57BL/6J mice. Behav Brain Res 2005, 159:145-151. 10.1016/j.bbr.2004.10.011, 15795008.
51. Shaw KN, Commins S, O'Mara SM. Lipopolysaccharide causes deficits in spatial learning in the water maze but not in BDNF expression in the rat dentate gyrus. Behav Brain Res 2001, 124:47-54. 10.1016/S0166-4328(01)00232-7, 11423165.
52. Fink MP, Fiallo V, Stein KL, Gardiner WM. Systemic and regional hemodynamic changes after intraperitoneal endotoxin in rabbits: development of a new model of the clinical syndrome of hyperdynamic sepsis. Circ Shock 1987, 22:73-81.
53. Opal SM. The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis. Int J Med Microbiol 2007, 297:365-377. 10.1016/j.ijmm.2007.03.006, 17452016.
54. Beishuizen A, Thijs LG. Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis. J Endotox Res 2003, 9:3-24.
55. Gabellec MM, Griffais R, Fillion G, Haour F. Expression of interleukin 1 alpha, interleukin 1 beta and interleukin 1 receptor antagonist mRNA in mouse brain: regulation by bacterial lipopolysaccharide (LPS) treatment. Brain Res Mol Brain Res 1995, 31:122-130.
56. Hansen MK, Nguyen KT, Goehler LE, Gaykema RP, Fleshner M, Maier SF, Watkins LR. Effects of vagotomy on lipopolysaccharide-induced brain interleukin-1beta protein in rats. Auton Neurosci 2000, 85:119-126. 10.1016/S1566-0702(00)00230-7, 11189018.
57. Turrin NP, Gayle D, Ilyin SE, Flynn MC, Langhans W, Schwartz GJ, Plata-Salaman CR. Pro-inflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide. Brain Res Bull 2001, 54:443-453. 10.1016/S0361-9230(01)00445-2, 11306198.
58. Jann B, Reske K, Jann K. Heterogeneity of lipopolysaccharides. Analysis of polysaccharide chain lengths by sodium dodecylsulfate-polyacrylamide gel electrophoresis. Eur J Biochem 1975, 60:239-246. 10.1111/j.1432-1033.1975.tb20996.x, 1107034.
59. Banks WA, Robinson SM. Minimal penetration of lipopolysaccharide across the murine blood-brain barrier. Brain Behav Immun 2010, 24:102-109. 10.1016/j.bbi.2009.09.001, 2789209, 19735725.
60. Laflamme N, Rivest S. Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components. FASEB J 2001, 15:155-163. 10.1096/fj.00-0339com, 11149903.
61. Thibeault I, Laflamme N, Rivest S. Regulation of the gene encoding the monocyte chemoattractant protein (MCP-1) in the mouse and rat brain in response to circulating LPS and proinflammatory cytokines. J Comp Neurol 2001, 434:461-477. 10.1002/cne.1187, 11343293.
62. Tomás-Camardiel M, Rite I, Herrera AJ, de Pablos RM, Cano J, Machado A, Venero JL. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol Dis 2004, 16:190-201. 10.1016/j.nbd.2004.01.010, 15207276.
63. Ji KA, Yang MS, Jeong HK, Min KJ, Kang SH, Jou I, Joe EH. Resident microglia die and infiltrated neutrophils and monocytes become major inflammatory cells in lipopolysaccharide-injected brain. Glia 2007, 55:1577-1588. 10.1002/glia.20571, 17823975.
64. Jeong HK, Jou I, Joe EH. Systemic LPS administration induces brain inflammation but not dopaminergic neuronal death in the substantia nigra. Exp Mol Med 2010, 12:823-832.
65. Hart PS, Zhang Y, Firatli E, Uygur C, Lotfazar M, Michalec MD, Marks JJ, Lu X, Coates B. Identification of cathepsin C mutations in ethnically diverse Papillon-Lefèvre syndrome patients. J Med Genet 2001, 37:927-932.
66. Xi G, Reiser G, Keep RF. The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?. J Neurochem 2003, 84:3-9.
67. Striggow F, Riek M, Breder J, Henrich-Noack P, Reymann KG, Reiser G. The protease thrombin is an endogenous mediator of hippocampal neuroprotection against ischemia at low concentrations but causes degeneration at high concentrations. Proc Natl Acad Sci USA 2000, 97:2264-2269. 10.1073/pnas.040552897, 15789, 10681455.
68. Sawada K, Nishibori M, Nakaya N, Wang Z, Saeki K. Purification and characterization of a trypsin-like serine proteinase from rat brain slices that degrades laminin and type IV collagen and stimulates protease-activated receptor-2. J Neurochem 2000, 74:1731-1738.
69. Perry VH, Gordon S. Macrophages and the nervous system. Int Rev Cytol 1991, 125:203-244.
70. Nathan CF. Secretory products of macrophages. J Clin Invest 1987, 79:319-326. 10.1172/JCI112815, 424063, 3543052.
71. Giulian D, Corpuz M. Microglial secretion products and their impact on the nervous system. Adv Neurol 1993, 59:315-320.
72. Dahl SW, Halkier T, Lauritzen C, Dolenc I, Pedersen J, Turk V, Turk B. Human recombinant pro-dipeptidyl peptidase I (cathepsin C) can be activated by cathepsin L and S but not by autocatalytic processing. Biochemistry 2001, 40:1671-1678. 10.1021/bi001693z, 11327826.